ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions
View by Date

Monday, November 8, 2021

8:30AM-10:30AM
Abstract Number: 1211
Evaluation of the Cervical Involvement Frequency and Associated Risk Factors in Patients with Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)
8:30AM-10:30AM
Abstract Number: 1029
Evaluation of the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Population-Based Registry
Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)
8:30AM-10:30AM
Abstract Number: 1216
Evidence of a Tendency for Localized Recurrence of Arthritis in Rheumatoid Arthritis Patients
RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)
8:30AM-10:30AM
Abstract Number: 1214
Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)
8:30AM-10:30AM
Abstract Number: 1124
Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Osteoarthritis – Clinical Poster III (1118–1134)
8:30AM-10:30AM
Abstract Number: 1001
Exosomes Mediate a Cooperative Mechanism of Macrophage/Fibroblast Activation in Systemic Sclerosis
Innate Immunity Poster (0992–1006)
8:30AM-10:30AM
Abstract Number: 1009
Expanded B Cell-Helper T Cells in ANA+ Oligoarticular Juvenile Idiopathic Arthritis
Pediatric Rheumatology – Basic Science Poster (1007–1013)
8:30AM-10:30AM
Abstract Number: 1176
Experience from TheMednet: Online Rheumatology Physician Social Network
Professional Education Poster (1170–1195)
8:30AM-10:30AM
Abstract Number: 1151
Experiences and Finding Meaning Among Latin Americans Living with Lupus: Learning from Social Media Narratives by Patients and Their Social Network
Patient Education/Community Programs Poster (1150–1152)
8:30AM-10:30AM
Abstract Number: 1067
Experiences of Self-Care During the COVID-19 Pandemic Among Individuals with Rheumatoid Arthritis: A Qualitative Study
Health Services Research Poster II: Care Models and Innovation (1061–1082)
8:30AM-10:30AM
Abstract Number: 1070
Experiences of Wearable Technology by Persons with Knee Osteoarthritis Participating in a Physical Activity Counselling Intervention Study: A Relational Ethics Lens
Health Services Research Poster II: Care Models and Innovation (1061–1082)
8:30AM-10:30AM
Abstract Number: 1071
Experiences Using Wearable Technology by Persons with Rheumatoid Arthritis Participating in a Physical Activity Counselling Intervention Study: A Relational Ethics Analysis
Health Services Research Poster II: Care Models and Innovation (1061–1082)
8:30AM-10:30AM
Abstract Number: 1162
Exploring Cannabis Use and Perspectives Among Psoriatic Disease Patients
Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)
8:30AM-10:30AM
Abstract Number: 1047
Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain
Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)
8:30AM-10:30AM
Abstract Number: 1094
Extremely Elevated Erythrocyte Sedimentation Rate Revisited in Rheumatic Diseases: Flare-Up or Infection? Single Centre Retrospective Analysis
Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)
  • «Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 32
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology